Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from PODD

Insulet Stock: Analyst Estimates & Ratings

Insulet has significantly outpaced the broader market over the past year, and analysts remain very bullish on the stock’s prospects.

Barchart

Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5

Insulet Corporation (NASDAQ:PODD) reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents.

Benzinga

What to Expect From Insulet's Q2 2025 Earnings Report

Insulet is expected to release its second-quarter earnings next month, with analysts anticipating double-digit bottom-line growth.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?

Insulet has outperformed the Medical Devices industry over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

Do Wall Street Analysts Like Insulet Stock?

Insulet has significantly outpaced the broader market over the past year, and analysts remain bullish on the stock’s prospects.

Barchart

S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points

Visa has topped a buy point, while fellow S&P 500 component Insulet gapped out of a base, leading five stocks on this weekend watchlist.

Investors Business Daily

Here's What to Expect From Insulet's Next Earnings Report

Insulet is set to release its first-quarter results next month, and analysts expect a double-digit earnings growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Insulet Stock: Is PODD Outperforming the Healthcare Sector?

As Insulet has outperformed relative to the healthcare sector over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Insulet Stock Outlook: Is Wall Street Bullish or Bearish?

Insulet has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

Earnings Preview: What to Expect From Insulet's Report

Insulet is scheduled to release its fiscal fourth-quarter earnings next month, and analysts project a double-digit profit decline.

Barchart

Is Insulet Stock Outperforming the Dow?

Insulet has outperformed the Dow recently, and analysts remain strongly optimistic about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Insulet Stock Will Climb or Sink?

As Insulet outperformed relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Barchart

Insulet's Quarterly Earnings Preview: What You Need to Know

Insulet will release its third-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Barchart

Is Insulet Stock Outperforming the Nasdaq?

Insulet has outperformed the Nasdaq Composite over the past year and analysts remain strongly bullish about the stock’s prospects.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is Wall Street Bullish or Bearish on Insulet Stock?

Despite Insulet’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Investors Business Daily

Insulet Surges After Eye-Popping Earnings Growth Wallops Expectations

Insulin pump-maker Insulet walloped earnings projections and delivered strong sales, leading PODD stock to jump Friday.

Investors Business Daily

AMD Stock, AI Play And New S&P 500 Member Lead 5 Stocks Near Buy Points

AMD and a new member of the S&P 500 lead this weekend's watch list of stocks that are riding positive trends, despite the tough economy.

Investors Business Daily

Insulet Joins S&P 500 And Gets Ready To Pump Up New Breakout With 56% Growth

After Insulet jumped on news it was joining the S&P 500, PODD stock is wound up for a breakout with earnings due.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

5 S&P 500 Stocks Near Buy Points As Recession Fears Rise

Medical stocks are holding up amid economic and market uncertainty.

Investors Business Daily

Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally

Dow giant UnitedHealth is among 5 stocks holding key support while the overall market weakens.

Investors Business Daily

IBD Stock Of The Day: Why An Analyst Says The Rich Valuation For Insulet Is Justified

Diabetes devices maker Insulet is the IBD Stock Of The Day as PODD stock hovers in a buy zone near its 21-day moving average.

Investors Business Daily

Dow Jones Futures: Market Expects This From Fed Chief Powell; 5 Stocks In Buy Zones

Several stocks flashed buy signals as the market rallied heading into Fed chief Powell's speech. Here's what to expect.

Investors Business Daily

IBD Stock Of The Day Insulet Edges Closer To A Breakout On This 'Game Changer'

Insulet is the IBD Stock Of The Day as excitement around the company's new insulin pump, Omnipod 5, drives PODD stock closer to a breakout.

Benzinga

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter. According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

Benzinga

Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is 'Progressing Very Well'

Insulet Corporation (NASDAQ:PODD) posted Q1 profits of $27.8 million, or an EPS of $0.40, beating the consensus of $0.23. Q1 sales increased 17.1% Y/Y, or 19.3% in constant currency, to $295.4 million, exceeding the guidance range of 13% to 16% in constant currency and the consensus of $288.18 million. “We are off…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.